Skip to main content

Table 1 Patient characteristics

From: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

  CD UC
Patients number (n = 112) 84 28
Males/females 39/45 (46%/54%) 11/17 (39%/60%)
Mean age at TDM (SD) 36 years (10.9) 35 years (11.2)
Mean duration of adalimumab therapy (SD) 157.8 weeks (101.7) 70.1 weeks (58.0)
Age at onset (<16y/17-40y/>40y) 13/64/7 -
Localisation of Crohn’s disease (ileal/colon/ileocolon/upper GI/ileocolon + upper GI) 13/16/47/2/5 -
Extension of colitis (proctitis/left sided/extensive) - 0/19/9
Behaviour of CD (inflammatory/stricturing/penetrating/strict. + pen.) 29/18/27/10 -
Perianal disease in CD 42/84 (50%) -
Previous surgery 43/84 (48.8%) 0/28 (0%)
Smoking (yes/no/previous) 44/24/16 19/2/7
Previous 5-ASA 69/84 (82.1%) 26/28 (93%)
Previous steroid 76/84 (90.5%) 28/28 (100%)
Previous/concomitant AZA 67/84 (80%)/42/84 (50%) 20/28 (71.4%)/2/28 (28.6%)
Previous anti-TNF 50/84 (60.2%) 23/28 (82%)
Previous IFX/ADM/both 38/5/7 22/1/0
  1. (CD Crohn’s disease, UC Ulcerative colitis, SD Standard deviation, TDM Therapeutic drug monitoring, GI Gastrointestinal, 5-ASA 5-aminosalycilate, AZA Azathioprine, anti-TNF Anti-tumor necrosis factor, IFX Infliximab, ADM Adalimumab)